Condition: Absence Epilepsy · Jeavons Syndrome · Dravet Syndrome · Sponsor: Bright Minds Biosciences Pty Ltd
The study is a pilot, open-label, study to test whether BMB-101 is safe and effective in reducing the frequency of seizures in subjects with Absence Epilepsy including Epilepsy with Eyelid Myoclonia (also called Jeavons Syndrome) as well as Developmental Epileptic Encephalopathies such as Dravet and Lennox Gastaut. The study will last up to 6 months. There will be a 1 month screening period, then up to 3 months on open-label BMB-101 including titration and tapering/washout periods, and then a 1 month follow-up period. There will be 6 clinic visits.
This description comes directly from the study's public registry record.
Rachelle Kirk-Burnnand · +61 439615368 · rachelle@basebio.com.au
Always discuss trial participation with your own doctor first.
| The Prince of Wales Hospital | Randwick, New South Wales, Australia | Recruiting |
| Royal Brisbane and Womans Hospital | Herston, Queensland, Australia | Recruiting |
| St Vincent's Hospital Melbourne | Fitzroy, Victoria, Australia | Recruiting |
| Austin Health | Heidelberg, Victoria, Australia | Recruiting |
| Alfred Health | Melbourne, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06401538